N/A Completed N=63 Randomized Triple-blind Prevention

Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy

Breast Cancer · neuropathy

Source: ClinicalTrials.gov NCT01163682 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2023

Primary outcomePrimary: Change in Brief Pain Inventory-Short Form Score — 1.6; 0.6 Score on a scale — p=0.25

Summary

This study seeks to determine if 12 weeks of weekly electro-acupuncture will prevent or decrease neuropathic pain in breast cancer patients receiving 12 weekly treatments of taxane treatment.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Brief Pain Inventory-Short Form Score	1.6; 0.6	0.25
SECONDARY Change in FACT-TAX Score	-9.4; -8.4	0.09

Eligibility Criteria

Inclusion Criteria

Age>21 years
History of stage I-III breast cancer
Patient scheduled to be receiving weekly adjuvant or neo-adjuvant paclitaxel for 12 weeks
Signed informed consent

Exclusion Criteria

Previous treatment with acupuncture in the last 12 months
Diabetic Neuropathy or other neurological conditions
Inflammatory, metabolic or neuropathic arthropathies
Current narcotic use
Severe concomitant illnesses
Severe coagulopathy or bleeding disorder
Dermatological disease within the acupuncture area
Have a pacemaker

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01163682). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.